SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is gaining traction as a tokenized positivity movement on the Solana blockchain, particularly within the $PUMP ecosystem. The community is excited about the acquisition of the @wagmi Instagram handle and anticipates further growth, emphasizing a strong narrative and the potential for significant gains. Discussions also highlight its strong community, cultural relevance, and resilient price action, with many believing that "we're all gonna make it".

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

Q/C Technologies Inc.

QCLS is trending due to its pivot towards quantum computing for cryptocurrency applications, generating excitement around energy-efficient blockchain $BTC infrastructure. The community is discussing the potential of LightSolver's laser-based processing units and comparing QCLS to other quantum and crypto-related stocks like $RGTI and $QBTS. Traders are monitoring the stock's threshold list status and anticipating news regarding partnerships and potential contract announcements.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is gaining attention, with community members sharing links to dex screener and the project's website. There is discussion around a token burn and the coin's association with weed culture. Some users are comparing it to Bitcoin and highlighting its potential within the broader cannabis industry.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amidst discussions around government shutdowns and their potential impact, with community members debating political affiliations and economic consequences. Some are highlighting the stock's short squeeze potential, while others are criticizing the company's financials and leadership. The conversation includes broader political commentary, focusing on various policy issues and figures.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending due to recent purchase orders for its quantum computing systems, signaling increased commercial viability. The community is actively discussing the potential for a gamma squeeze and comparing RGTI to other high-growth tech stocks in the quantum computing sector. Despite some concerns about valuation, the overall sentiment reflects excitement about the future of quantum computing and RGTI's position in the industry.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

QBTS is trending as the quantum computing sector gains momentum, with community members discussing the potential impact of strategic partnerships and government initiatives. Bullish investors are anticipating further gains, while others remain skeptical about the company's valuation and profitability. Discussions also involve potential short squeezes and upcoming catalysts that could influence the stock's direction.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending as retail traders discuss a potential short squeeze, citing its collaboration with NVIDIA and government interest in quantum computing. Some traders point to the stock's high valuation and cash burn rate, while others highlight potential catalysts like government contracts and long-term growth in the sector. The community is actively debating dilution concerns and the validity of technical analysis on this stock.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

ONDS is trending as traders discuss its potential in the drone and IoT space, especially regarding defense applications and contracts. Community members are pointing to the company's recent moves, like partnerships and investments, as signs of growth. The stock is gaining attention due to increasing drone-related news and speculation around upcoming earnings and potential catalysts.

Aster is a next-generation decentralized exchange offering both Perpetual and Spot trading, designed as a one-stop onchain venue for global crypto traders. It features MEV-free, one-click execution in Simple Mode. Pro Mode adds 24/7 stock perpetuals, Hidden Orders, and grid trading, available across BNB Chain, Ethereum, Solana, and Arbitrum.  Its unique edge lies in the ability to offer liquid-staking tokens (asBNB) or yield-generating stablecoins (USDF) as collateral, unlocking unparalleled capital efficiency. Powered by Aster Chain, a high-performance and privacy-focused L1, and backed by YZi Labs, Aster is building the future of DeFi: fast, flexible, and community-first.  At the heart of this ecosystem is the $ASTER token, a core asset that decentralizes governance, drives growth, rewards participation, and supports long-term sustainability.

ASTERION

ASTER is trending amid discussions about potential manipulation and significant token movements, with some traders anticipating a price drop. Community members are debating its future, with bullish sentiments around potential airdrops and exchange listings countered by bearish concerns of a possible dump. The broader context involves its role as a decentralized exchange and comparisons to competitors, particularly within the ongoing DEX wars.

A multi-agent AI platform dissecting human nature’s first principles through iterative survival challenges and data-driven insights. Core dev has access to one of the founding partners of Two Sigma Ventures - the VC company of one of the biggest hedge funds in the world. Plans to raise seed round and scale after building organic foundation. Project devs are from academia space and are trying to bridge the gap between crypto and academia.

CortexZero

CortexZero is trending as community members highlight potential breakout opportunities, particularly for early entries via Phantom Wallet. Bullish sentiment appears to be building, with many suggesting it could be the 'next mover' within the Solana ecosystem. However, some caution it may be a scam due to ownership concentration.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Maze Therapeutics, Inc. (MAZE) on Thursday announced that it has entered into a securities purchase agreement for the private placement of its securities for gross proceeds of about $150 million. Shares of the company soared 56% in the pre-market session at the time of writing.The <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-announces-oversubscribed-1500-million-private">private placement</a> involves the sale of over four million shares of common stock at $16.25 &nbsp;apiece, implying a premium of over 1% from the stock’s closing price on Wednesday. The placement is expected to close on September 12, the company said, while adding that both new and existing investors will participate.The firm said that the private placement includes participation from Frazier Life Sciences, Deep Track Capital, Driehaus Capital Management, Janus Henderson Investors, Logos Capital, TCGX, and Venrock Healthcare Capital Partners, as well as other healthcare-dedicated funds.The South San Francisco-based biopharmaceutical company is developing medicines for patients with kidney and metabolic diseases. It stated that it expects to utilize the proceeds from the placement to advance the development of MZE829 in patients with APOL1-mediated kidney disease, initiate mid-stage clinical trials of MZE782 in both phenylketonuria (PKU) and chronic kidney disease (CKD), and continue progress on its research and discovery programs. The company also intends to use the funds for working capital and other general corporate purposes.Last month, the company said that it ended June with cash and cash equivalents of $264.5 million, which it expects will fund operations into the second half of 2027.Separately, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.mazetx.com/news-releases/news-release-details/maze-therapeutics-announces-positive-first-human-results-phase-1">also</a> announced positive clinical results from an early-stage study of MZE782, including “an excellent safety profile, robust target engagement and compelling pharmacodynamic effects.” The firm stated that the study data in 112 healthy volunteers exceeded expectations, enabling mid-stage advancement in the treatment of both PKU and CKD in 2026.Maze went public in January. The stock is up by 0.4% since its listing.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-in-consolidation-mike-novogratz-sees-solana-ethereum-taking-spotlight/chwN1oPRdvg">‘Bitcoin in Consolidation’ – Galaxy’s Mike Novogratz Reportedly Sees Solana, Ethereum Taking Spotlight For Now</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Maze Therapeutics Stock Just Shot Up 56% Pre-Market Today – Here’s What Happened

The company announced a private placement for over four million shares of common stock at $16.25 apiece, representing a premium of over 1% from the stock’s closing price on Wednesday.

Equity

The company announced a private placement for over four million shares of common stock at $16.25 apiece, representing a premium of over 1% from the stock’s closing price on Wednesday.


Maze Therapeutics receives positive ratings following recent IPO

Investing.com --  Maze Therapeutics  Inc (NASDAQ:MAZE) received bullish coverage from multiple analysts, with Guggenheim, JPMorgan, and TD Cowen initiating Buy or Overweight ratings on the company given its potential in genetically targeted therapies.

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. Its pipeline includes the Compass platform, which allows it to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process to refer a variant functionalization. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman on August 29, 2017 and is headquartered in San Francisco, CA.

Maze Therapeutics Inc.

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

Current Price	$26.50
Prev Close	$25.81
Open	$26.01
Dividend Yield	N/A
50-Day Moving Average	$17.64
Beta	1.01
Avg. Volume	845,065.81
PE Ratio	-15.33

52-Week High	$28.37
52-Week Low	$6.71
Market Capitalization	$1.13B
EPS (Annual)	$0.0778
Price to Book	4.32
Revenue Per Employee	$1.34M
Enterprise Value/EBITDA	N/A

MAZE
Maze Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MAZE News

MAZE Maze Therapeutics Inc.